Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/YIC.0000000000000558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature.
J Psychopharmacol
December 2024
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Background: Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians.
Aim: This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression.
Venlafaxine treatment is associated with improved mood, but not decreased cocaine self-administration, in depressed people who use cocaine.
Pharmacol Biochem Behav
November 2024
Division on Substance Use Disorders, New York State Psychiatric Institute and Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Individuals seeking treatment for their cocaine use often report depressive systems and nearly half meet criteria for major depressive disorder (MDD). This descriptive study aimed to assess the effects of the antidepressant venlafaxine alone and in combination with gabapentin on depressive symptoms, subjective effects of cocaine, and cocaine self-administration in depressed and non-depressed people who use cocaine. The effects of medication condition on mood and on the effects of smoked cocaine were compared between a group of clinically depressed people who use cocaine (n = 5) and a control group of non-depressed people who use cocaine (n = 5) using laboratory-based measures.
View Article and Find Full Text PDFWhen antidepressants meet the gut microbiota: implications and challenges.
Int Clin Psychopharmacol
January 2025
Université Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations (CESP), MOODS UMR1018, CESP-Inserm, Team Moods, Faculté de Médecine, Le Kremin-Bicêtre.
Optimized psilocybin production in tryptophan catabolism-repressed fungi.
Microb Biotechnol
November 2024
Bio Pilot Plant, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental disorders such as therapy-refractory depression, alcohol use disorder and anorexia nervosa. Psilocybin has been designated a 'Breakthrough Therapy' by the US Food and Drug Administration, and therefore a sustainable production process must be established to meet future market demands. Here, we present the development of an in vivo psilocybin production chassis based on repression of l-tryptophan catabolism.
View Article and Find Full Text PDFDetermination of natural populations to be included in breeding program in St. John's wort species ( L.).
PeerJ
October 2024
Medicinal Aromatic Plants Section, Bati Akdeniz Agricultural Research Institute, Antalya, Turkey.
St. John's wort ( L.) is a medicinal and aromatic plant of rapidly increasing importance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!